Approximately 30 subjects will be enrolled in this double-blind, placebo-controlled study. The randomization will be stratified 2:1 into the LYC-30937-EC cohort (2) or the placebo cohort (1). The active cohort will receive LYC-30937-EC 25 mg once daily, which demonstrated safety and tolerability in Phase I trials.~The study is designed for patients with previously diagnosed moderate chronic plaque-type psoriasis and consists of the following:~Screening period (initials assessment and eligibility scoring)~Day 1: confirm eligibility, baseline efficacy assessments (PASI, IGA), randomize and initiate dosing~Week 2: safety assessments including vital signs, body temperature, physical exam, clinical labs will be performed~Week 4: efficacy (PASI, IGA) and safety assessments including vital signs, body temperature, physical exam, and clinical labs will be performed~Week 8: efficacy (PASI, IGA) and safety assessments including vital signs, body temperature, physical exam, and clinical labs will be performed~Week 12: final efficacy assessments (PASI, IGA), safety assessments including vital signs, body temperature, physical exam, ECG, and clinical labs will be performed~Week 14: final safety assessments including vital signs, body temperature, and clinical labs
The objective of this Phase 2 trial is to determine the efficacy and safety of LYC-30937-EC in patients with moderate plaque-type psoriasis.